Cefpodoxime proxetil, an ester prodrug of cefpodoxime, is an oral third-generation cephalosporin antibiotic that is used for the treatment of odontogenic infections such as periodontitis, pericoronitis, and osteitis of jaw. However, there are only a few studies on cephalosporin concentrations in human oral tissues. The present study therefore was undertaken to determine cefpodoxime concentrations in human oral tissues following oral administration of cefpodoxime proxetil. Cefpodoxime concentrations in human serum, gingiva, mandibular bone, and dental follicle following a single oral administration of 200-mg cefpodoxime proxetil were measured by a paper disk method. The mean peak concentrations in serum, gingiva, mandibular bone, and dental follicle occurred at the same time point, 3 hours post-dose, and were 3.07 ± 0.96 μg/mL, 1.16 ± 0.35 μg/g, 0.60 ± 0.27 μg/g, and 1.13 ± 0.34 μg/g, respectively. Mean cefpodoxime concentration ratios of gingiva / serum, mandibular bone / serum, and dental follicle / serum at the peak time were 0.40 ± 0.15, 0.20 ± 0.05, and 0.37 ± 0.03, respectively. Mean concentrations in gingiva, mandibular bone, and dental follicle at the peak time exceeded the minimum inhibitory concentration for 80% of clinically isolated strains of oral streptococci. Therefore, cefpodoxime proxetil may be a valuable antimicrobial agent for the treatment of odontogenic infection.
Introduction
Cefpodoxime proxetil, an oral third-generation cephalosporin antibiotic, is used for the treatment of odontogenic infections such as periodontitis, pericoronitis, and osteitis of jaw. The compound is a pro-drug that is cleaved by nonspecific carboxyl esterase activities in the intestinal epithelium to yield the active moiety, cefpodoxime (1) .
Cefpodoxime exerts antibacterial activity by binding to penicillin-binding proteins (notably PBP1 and PBP3) and inhibiting bacterial cell wall synthesis (2, 3) . Cefpodoxime is highly resistant to hydrolysis by the β-lactamases produced by various species of bacteria, providing the drug with a broad spectrum of in vitro activity against many common gram-positive and gram-negative bacteria such as Staphylococcus aureus, streptococci, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Providencia rettgeri, and Haemophilus influenzae (4) (5) (6) (7) (8) .
Cefpodoxime proxetil is well tolerated and has safety and side-effects profiles that are similar to other third-generation cephalosporins (9) . The pro-drug shows a good absorption profile, with an absolute bioavailability of cefpodoxime of approximately 50% following oral administration of a 100-mg cefpodoxime proxetil tablet (10) . The larger mean value for peak concentration of cefpodoxime was determined from subjects receiving any meals compared to fasted subjects, and the mean peak time of cefpodoxime from subjects receiving any meals was longer than that from fasted subjects. Thus, subjects in the fasting state had lower estimate of area under the plasma cefpodoxime concentration-time curve (AUC) relative to the AUC estimate from the subjects receiving any meals.
Higher plasma levels were produced when cefpodoxime proxetil was taken with food or when a low gastric pH was present (11) (12) (13) .
Previous studies have reported cephalosporin concentrations in human oral tissues and discussed penetration of the drug into oral tissue (14) (15) (16) (17) (18) (19) . However, limited information is available regarding cefpodoxime concentrations in human oral tissues following a single oral administration of cefpodoxime proxetil (20) . Therefore, the present study was undertaken to determine cefpodoxime concentrations in human serum, gingiva, mandibular bone, and dental follicle following a single oral administration of cefpodoxime proxetil for appropriate medication to odontogenic infection. 
Materials and Methods

Patients
Statistical analysis
All data were expressed as the mean ± SD. Statistical analysis was made by using One-Way ANOVA with the Bonferroni post-hoc test to determine the significance level of the difference between mean values. P values of < 0.05
were considered statistically significant.
Results
Serum
The distribution of cefpodoxime concentrations in serum is shown in 
Dental follicle
The distribution of cefpodoxime concentrations in dental follicle is shown in (11, 12) . In the present study, the mean peak serum concentration of cefpodoxime was 3.07 ± 0.96 μg/mL and occurred at 3 hours after dosing with cefpodoxime proxetil.
Thus, our results yielded values similar to those previously reported for non-fasting subjects. Our study examined non-fasted outpatients, treated in general practice dentistry, who were administered cefpodoxime proxetil in combination with 200 ml of water at 1-2 hours after meals. It is difficult to control accurately the conditions under which patients take medicine. However, under conditions of administration in the present study, serum cefpodoxime levels were sufficient for exerting antibacterial activity.
Although these were the only conditions that we were able to control, the results were applicable to clinical practice.
Ratios of mean peak concentrations in oral tissue / serum are summarized for seven cephalosporins in Table 1( [14] [15] [16] [17] [18] [19] .
For a given tissue, the ratios were highly similar among the )and in the corresponding serum (μg/mL) at various sampling times after a single oral administration of cefpodoxime proxetil. Vertical bar indicates SD. a P < 0.001 compared to gingiva, b P < 0.001 compared to mandibular bone, and c P < 0.001 compared to dental follicle.
Our study revealed that cefpodoxime concentrations in serum at 1.5 to 4 hours were significantly higher than those in gingiva, mandibular bone, and dental follicle. However, cefpodoxime concentrations did not differ significantly among gingiva, mandibular bone, and dental follicle. These results suggest that cefpodoxime shows a similar distribution to gingiva, mandibular bone, and dental follicle. The minimum inhibitory concentration of cefpodoxime for 80%
(MIC 80 )of clinically isolated strains of oral streptococci is 0.39 μg/mL (8) . Thus, in our study, the mean peak concentrations of cefpodoxime in gingiva, mandibular bone, and dental follicles following a single oral administration of 200-mg cefpodoxime proxetil exceeded this MIC 80 . These results suggest that cefpodoxime proxetil may be a valuable antimicrobial agent for the treatment of odontogenic infection. However, in several subjects the cefpodoxime concentrations in gingiva (4 out of 38 cases) at 1 hour, in dental follicles(3 out of 38 cases)at 1 hour, and in mandibular bone(9 out of 38 cases)at 1 to 2 hours after administration did not exceed the MIC 80 . Therefore, prophylactic single oral administration of cefpodoxime proxetil should be performed more than two hours before surgery.
In conclusion, we assessed cefpodoxime concentrations in human serum, gingiva, mandibular bone, and dental follicle 
